The increasing resistance to intravenous artemisinin therapy for malaria highlights the urgent need for new treatments that offer better patient compliance and a single-dose cure to address this global health threat. Novartis AG recently presented the discovery, development and evaluation of aminoisoquinolines as fast-acting intravenous therapeutic agents for severe malaria treatment.
Incretin therapies based on GLP-1 receptor agonism aid in the loss of weight in obesity, but a relevant part of this loss (25%-40%) is attributed to loss of lean muscle mass, which raises the risk of sarcopenia. Keros Therapeutics Inc. has presented data on RKER-065, a novel modified ActRII-Fc ligand trap that inhibits myostatin and activins and promotes muscle formation.
How do exercise and insulin collaborate in metabolism? The European Association for the Study of Diabetes (EASD) and the Novo Nordisk Foundation recognized the work of Juleen Zierath in this topic with the Diabetes Prize for Excellence at their recent annual meeting.
Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
2A Biosciences Inc. has divulged compounds acting as 5-HT2A and 5-HT2C receptor agonists reported to be useful for the treatment of atopic dermatitis, conjunctivitis, Crohn’s disease, type 2 diabetes, obsessive-compulsive disorder, rheumatoid arthritis, schizophrenia and traumatic brain injury, among others.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5)/methylosome protein 50 (MEP50) interaction inhibitors reported to be useful for the treatment of cancer.
Shenzhen Genuine Biotech Co. Ltd. has disclosed stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer. An exemplified compound significantly reduced tumor growth in experiments.
Cincera Therapeutics Pty Ltd. and Monash University co-presented the phenotypic drug discovery of CIN-244, a novel MRTF/SRF pathway inhibitor reported to be potentially useful for the treatment of fibrotic disease, particularly liver, lung and renal fibrosis.
Researchers from Kyowa Kirin Co. Ltd. presented preclinical data for the novel bispecific CD40-EpCAM antibody KK-2269, being developed for the treatment of cancer.